Renewal of the Syracuse Hematology-Oncology CCOP grant will enable us to continue to build upon efforts to promote quality clinical cancer research in the geographic region surrounding Syracuse, New York through participation in NCI sponsored treatment and cancer control studies. Syracuse Hematology-Oncology CCOP (Hematology-Oncology Associates of CNY) is committed to providing patients ready access to current cancer treatment, control and prevention trials. We are currently following hundreds of patients on cancer treatment, control and prevention trials. Continuation of the grant will not only allow us to continue to follow these patients, but to accrue additional individuals to such studies. Our Research Coordinator, Clinical Research Associates and Nurse Practitioner continue to work closely with the entire staff of Hematology-Oncology Associates of CNY to identify eligible patients for treatment and symptom control studies. We actively recruit high-risk individuals from a large area of Central New York for cancer prevention studies. The availability of a wide range of treatment and cancer control protocols improves the overall care of cancer patients in our community. The entire CCOP staff continues to not only provide """"""""state of the art"""""""" care to our patients but to serve as a valuable resource to the local health care providers and to educate the entire CNY community in terms of cancer treatment and prevention. Our goal is to maintain our CCOP at a high level in terms of quantity and quality and to further increase our efforts in terms of cancer prevention. ? ? ? COLLABORATING INSTITUTIONS: ? ? Hematology-Oncology Associates of CNY, East Syracuse, New York ? Hematology-Oncology Associates of CNY, Camillus, New York ? Community General Hospital, Syracuse, New York ? Crouse Hospital, Syracuse, New York ? St. Joseph's Hospital Health Center, Syracuse, New York ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045389-22
Application #
7489980
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Kelaghan, Joseph
Project Start
1987-07-21
Project End
2009-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
22
Fiscal Year
2008
Total Cost
$575,881
Indirect Cost
Name
Hematology-Oncology Associates/Ctl NY
Department
Type
DUNS #
101317097
City
East Syracuse
State
NY
Country
United States
Zip Code
13057
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20

Showing the most recent 10 out of 66 publications